thalidomide has been researched along with epirubicin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bojko, P; Brandhorst, D; Buttkereit, U; Ebeling, P; Flasshove, M; Hense, J; Hoiczyk, M; Metz, K; Moritz, T; Nowrousian, MR; Opalka, B; Schütt, P; Seeber, S | 1 |
| Hu, X; Huang, C; Lü, S; Ni, X; Qiu, H; Wang, J; Xu, X; Yang, J | 1 |
| Chongmei, H; Hui, C; Jianmin, Y; Shuqing, L; Wang, J | 1 |
| Cao, C; Kai, S; Liu, T; Wang, L; Xiang, B; Zhu, H | 1 |
| An, Y; Chen, T; Chen, Y; Dong, Y; Fu, L; Jin, B; Jin, F; Jin, X; Liu, J; Liu, Y; Luo, Y; Man, L; Qu, J; Qu, X; Shi, J; Sun, T; Teng, Y; Teng, Z; Wang, J; Wang, Z; Wen, F; Xie, X; Yu, P; Yuan, C; Zhang, J; Zhang, L; Zhang, X; Zhao, M; Zhou, L; Zhu, Z | 1 |
| Gourd, E | 1 |
2 review(s) available for thalidomide and epirubicin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Duodenum; Epirubicin; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pyrazines; Remission Induction; Stomach; Thalidomide; Tomography, X-Ray Computed; Vincristine | 2014 |
3 trial(s) available for thalidomide and epirubicin
| Article | Year |
|---|---|
Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Epirubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Remission Induction; Thalidomide; Vincristine | 2005 |
Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Boronic Acids; Bortezomib; Dexamethasone; Epirubicin; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome | 2009 |
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Epirubicin; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Thalidomide; Vomiting; Young Adult | 2017 |
5 other study(ies) available for thalidomide and epirubicin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Proteasome Endopeptidase Complex; Pyrazines; Thalidomide; Up-Regulation | 2011 |
Thalidomide reduces chemotherapy-induced vomiting.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Epirubicin; Humans; Isoquinolines; Palonosetron; Quality of Life; Quinuclidines; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome; Vomiting | 2017 |